NASDAQ:AIMT - Aimmune Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.61 -0.81 (-3.46 %) (As of 12/14/2018 09:09 AM ET)Previous Close$23.42Today's Range$22.03 - $23.726052-Week Range$21.47 - $42.00Volume515,276 shsAverage Volume686,917 shsMarket Capitalization$1.38 billionP/E Ratio-8.66Dividend YieldN/ABeta-0.13 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A Webwww.aimmune.com Phone650-614-5220 Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Price-To-Earnings Trailing P/E Ratio-8.66 Forward P/E Ratio-6.28 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book6.46 Profitability EPS (Most Recent Fiscal Year)($2.61) Net Income$-131,320,000.00 Net MarginsN/A Return on Equity-74.83% Return on Assets-65.91% Miscellaneous Employees131 Outstanding Shares58,730,000Market Cap$1.38 billion OptionableOptionable Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.03. View Aimmune Therapeutics' Earnings History. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Aimmune Therapeutics. What price target have analysts set for AIMT? 10 brokerages have issued 12-month target prices for Aimmune Therapeutics' stock. Their forecasts range from $30.00 to $80.00. On average, they anticipate Aimmune Therapeutics' share price to reach $51.5010 in the next year. This suggests a possible upside of 127.8% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics. What is the consensus analysts' recommendation for Aimmune Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics. What are Wall Street analysts saying about Aimmune Therapeutics stock? Here are some recent quotes from research analysts about Aimmune Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ". We are assuming coverage of AIMT with an Overweight rating and a 12-month PT of $64 based on lead asset AR101 in peanut allergy. Given the growing unmet clinical need in PA, ‘101 has Track designations, and we believe a high regulatory PoS exists based on data from the P3 PALISADE study. Full study data were recently published in the NEJM, validating the results and further enhancing our conviction given the notably reduced use of rescue epinephrine during the DBPCFC and limited use during updosing." (12/2/2018) 2. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (7/24/2018) Has Aimmune Therapeutics been receiving favorable news coverage? Media coverage about AIMT stock has trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aimmune Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include GALAPAGOS NV/S (GLPG), Amarin (AMRN), Catalent (CTLT), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), FibroGen (FGEN), Array Biopharma (ARRY), Horizon Pharma (HZNP) and Emergent Biosolutions (EBS). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the folowing people: Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 58)Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 51)Dr. Daniel C. Adelman, Chief Medical Officer (Age 61)Dr. Stephen George Dilly, Special Advisor (Age 58) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO. Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.81%), Vanguard Group Inc. (6.09%), Vanguard Group Inc (6.09%), Foresite Capital Management II LLC (5.62%), FMR LLC (3.61%) and Aisling Capital LLC (3.40%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics. Which institutional investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Aisling Capital LLC, Sofinnova Ventures Inc, Foresite Capital Management II LLC, Foresite Capital Management III LLC, C WorldWide Group Holding A S and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly and Susan E Barrowcliffe. View Insider Buying and Selling for Aimmune Therapeutics. Which institutional investors are buying Aimmune Therapeutics stock? AIMT stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., GW&K Investment Management LLC, Vanguard Group Inc, Vanguard Group Inc., Emerald Mutual Fund Advisers Trust, Massachusetts Financial Services Co. MA and Emerald Advisers Inc. PA. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $22.61. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $1.38 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is http://www.aimmune.com. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 501MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What are catch-up contributions?